Answers are grounded in this paper and cite their sources.
A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for identifying the optimal therapy for a patient with a myeloid malignancy should rely most on the patient's characteristics (particularly age and fitness/frailty) and disease cytogenetic and mutational profile, with less reliance on the bone marrow blast percentage.
No takes yet. Share an insight, caveat, or question.
DiNardo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: